• Bausch + Lomb recently secured FDA 510(k) clearance for its Bi-Blade+ vitrectomy cutter and Adaptive Fluidics upgrade while launching the enVista Envy intraocular lens in Europe and showcasing an expanded portfolio at the ASCRS 2026 meeting.
• Together, these advances deepen the company’s presence in premium surgical vision care by emphasizing intraocular pressure stability, surgical efficiency and full-range vision options.
• We’ll now explore how the Bi-Blade+ and Adaptive Fluidics clearance may influence Bausch + Lomb’s existing investment narrative in eye health.

Uncover the next big thing with 25 elite penny stocks that balance risk and reward.

Bausch + Lomb Investment Narrative Recap

To own Bausch + Lomb, you need to believe in a broad, durable eye health franchise across Pharma, Vision Care and Surgical, with improving profitability as Vision 27 efficiencies build. The Bi-Blade+ and Adaptive Fluidics clearance strengthens the higher value surgical portfolio, but does not obviously change the most important near term catalyst, which remains premium IOL recovery, or the key risk that execution on margin expansion and pipeline uptake could disappoint.

Among recent announcements, the European rollout of the preloaded enVista Envy IOLs feels most connected to this story. It directly supports the premium IOL catalyst that analysts are watching, while the Bi-Blade+ and Adaptive Fluidics clearance reinforces Bausch + Lomb’s relevance in complex retinal procedures. Together, they show how the Surgical segment is increasingly anchored in higher acuity, premium offerings that could matter for mix and earnings quality over time.

Yet, alongside these advances, investors should also be aware of how dependent margins still are on successfully scaling these newer premium surgical platforms...

Bausch + Lomb's narrative projects $5.9 billion revenue and $252.2 million earnings by 2028. This requires 5.7% yearly revenue growth and a $557.2 million earnings increase from $-305.0 million today.

Uncover how Bausch + Lomb's forecasts yield a $17.25 fair value, a 3% upside to its current price.

Exploring Other Perspectives

Some of the lowest estimate analysts were assuming only about US$5.8 billion of revenue and US$247.0 million of earnings by 2029, so if you think Bi Blade+ plus Adaptive Fluidics and premium IOLs can do more than that, you are already less pessimistic than they are.

Explore 5 other fair value estimates on Bausch + Lomb - why the stock might be worth just $17.25!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Bausch + Lomb research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Bausch + Lomb research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Bausch + Lomb's overall financial health at a glance.

No Opportunity In Bausch + Lomb?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• We've uncovered the 11 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Invest in the nuclear renaissance through our list of 93 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.